Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

16. Februar 2022 07:00 ET | Quelle: Helsinn Healthcare S.A.

Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico

Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico Toronto, Ontario and Lugano, Switzerland, February 16, 2022 ...
20. August 2020 09:00 ET | Quelle: Helsinn Healthcare S.A.

Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US

Helsinn Group announces AKYNZEO® injection – a new liquid IV solution – now available in the US Lugano, Switzerland, August 20, 2020 – Helsinn, a Swiss pharmaceutical group focused on building...
20. April 2020 08:30 ET | Quelle: Helsinn Healthcare S.A.

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis

Helsinn Therapeutics (U.S.), Inc. waives copay fees for cancer-treating drug VALCHLOR® (mechlorethamine) gel to ensure eligible patients have access to treatment during the COVID-19 crisis Iselin,...
12. Dezember 2018 08:00 ET | Quelle: Helsinn Healthcare S.A.

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US

Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...